#
Title
1

Anne-Marie Dingemans; Isabelle Opiz; Corinne Faivre-Finn on a consensus definition of stage III Non-Small Cell Lung Cancer technical resectability

2

Anne Holland and Christine McDonald

3

Marion Moseby-Knappe on Blood biomarkers for the prediction of outcome after cardiac arrest

4

Sailesh Kotecha on Prematurity-associated lung disease

5

Neil Greening and Hnin Aung on Multidimensional prognostic risk stratification of COPD exacerbations

6

Finn McQuaid and Matthew Saunders on Tuberculosis and Climate change

7

Toby Maher on ENV-101 in patients with idiopathic pulmonary fibrosis

8

Guy Brusselle and Celeste Porsbjerg on State-of-the-art insights into prevention, development, and management of asthma

9

Joan Soriano on Global Epidemiology of Respiratory Disease

10

Carole Mitnick & Lorenzo Guglielmetti on the ENDTB-Q trial

11

Lorenzo Guglielmetti parla del trial clinico ENDTB-Q (in Italian)

12

Laura Garriga-Grimau on bronchiectasis in children and young people

13

Marcus J Schultz and Prashant Nasa on defining and subphenotyping ARDS

14

Hjalmar Bouma on sepsis in patients who are immunocompromised

15

Simon Wolf on pulmonary embolism in children and adolescents in the US during 2016 and 2019

16

Sandeep Sahay and Franck Rahaghi on future treatment paradigms in pulmonary arterial hypertension

17

Sergio Harari sul trattamento della linfangioleiomiomatosi (LAM) (in Italian)

18

Sergio Harari on the treatment of lymphangioleiomyomatosis (LAM)

19

Robert Kullberg on empirical antibiotics for Sepsis

20

Heather Zar on early-life RSV disease and long-term respiratory health

21

Margaux Mesle on lives saved by COVID-19 vaccination

22

James Hull on protecting the respiratory health of athletes

23

Eric Lim on treatments for pleural mesothelioma

24

Anne Chang on the burden of chronic respiratory diseases in Indigenous people

25

Daniel Steinfort and Shankar Siva on radiotherapy field planning in patients with NSCLC

26

Daniel Prieto-Alhambra, Annika Jödicke, and Martí Català on vaccination to prevent Long COVID

27

Sarah Gorst and Tim Nicholson on long COVID outcomes

28

Betty Raman on multiorgan MRI abnormalities after hospitalisation with COVID-19

29

Keith Chappell on a bivalent recombinant vaccine for COVID-19

30

James Chalmers on bronchiectasis across Europe

31

Richard Costello on management of uncontrolled asthma

32

Keiju Aokage on segmentectomy for ground-glass-dominant lung cancer

33

Carol Hodgson on post-discharge outcomes for ECMO patients

34

Emma Grainger on 10 years of The Lancet Respiratory Medicine

35

Vivienne Kahlmann and Catharina Moor on the TIRED study

36

Yves Lacasse on long-term oxygen therapy for COPD

37

Rachael Evans on living with long COVID

38

Daniel Munblit and Dale Needham on core outcomes post-COVID-19

39

Daiana Stolz on antibiotic stewardship in pneumonia

40

Ablo Wachinou on sleep disordered breathing in Benin

41

Peter Openshaw and Felicity Liew on corticosteroids in the early in the treatment of COVID

42

Dinh Bui on preterm birth and lung function deficits

43

Ruvim Izĭckson on a joint flu and COVID-19 vaccine

44

Wisia Wedzicha on a vaccine for COPD

45

Eileen Rubin on patient-centered ARDS

46

Daniel Altmann on COVID boosters

47

Michael Kreuter on interstitial lung disease

48

Bairbre McNicholas and Jie Li on awake prone positioning and COVID-19

49

Charles Sprung and authors on end-of-life practices in ICUs globally

50

Christopher Brightling on tezepelumab in patients with moderate-to-severe uncontrolled asthma

51

Paul Verweij on COVID-19 associated aspergillosis

52

Ignacio Rubio on COVID-19 pathophysiology and phenotypes

53

Kiran Shekar on cytokine adsorption and severe COVID-19 pneumonia

54

Fan Chung on chronic cough and long COVID

55

Mepolizumab and the treatment of chronic rhinosinusitis

56

Inhaled budesonide in the treatment of early COVID-19

57

Tocilizumab and COVID-19

58

Interferon treatment and COVID-19

59

Evaluating deterioration in patients with acute COVID-19

60

Treatment options in patients with systemic sclerosis-associated interstitial lung disease

61

COVID-19 and severe influenza

62

The second wave and homeless populations